
Update on NEI / NIH Activities & Budget Overview ARVO Chairs and Research Directors

Paul A. Sieving, MD, PhD

National Eye Institute





NEI 40th Anniversary

Events and symposia to highlight NEI vision research portfolio, achievements, and future.

Symposia Series

2009

Vision Rehabilitation: *BLINDSIGHT* documentary, Erik Weihenmayer / April 3 Genetics and Genomics in Vision / April 16 - April 17 Optical Imaging and Biomedical Science / June 1 – 2 The 4th Jane Sayer Vision Research Lecture / October 22 Neuroscience and Vision / November 20

2010

Focus on Glaucoma / February 19
Novel Therapeutic Paradigms and Blindness / May 21

Appropriations History



Fiscal Year	Appropriation	% Change	
2005	\$664.8	2.1%	
2006	\$660.3	-0.7%	
2007	\$667.1	1.0%	
2008	\$669.5	0.4%	
2009 Est.	\$688.5	2.8%	

(Dollars in Millions)


FY 2009 Extramural **Budget Distribution**







NEI Extramural Grants - \$550.4M



□ RPGs - \$430.0 M

□ Core Centers - \$27.6 M


□ Coop.Clinical - \$51.3 M

■ Training & Career Dev. - \$30.0 M

■ Other Research - \$11.5 M

FY 2008 Extramural Budget by Program





FY 2008 Actual - \$669.5M Extramural Grants - \$537.3M


- □ Retinal Diseases Program \$244.8M
- □ Corneal Diseases Program \$63.5M
- ☐ Lens & Cataract Program \$33.9M
- Glaucoma & Optic Neuropathies Program \$59.3M
- Strabismus, Amblyopia, and Visual Processing Program (SAVP) \$116.3M
- Low Vision & Blindness Rehabilitation \$19.5M

2009 Budget Guidance




- Noncompeting awards funded at full committed levels
- 4 new K99 awards + 4 converting to R00 ("kangaroo")
- PI salary cap increased from \$191,300 to \$196,700
- Program Evaluation Tap increased 4.7%
- NIH Rare and Neglected Disease Initiative
 - \$682K from NEI (NIH Total \$24M)
- 41 new R01 grants for first-time PIs


Decline of Buying Power



NEI




RPG Average Total Costs



Excludes SBIR/STTR


(Dollars in Thousands)



RPG Number of Awards



NEI



^{*} Excludes SBIR/STTR


RPG Success Rate History



	2004 Actual	2005 Actual	2006 Actual	2007 Actual	2008 Actual	2009 Est.
Competing RPGs	323	289	258	262	279	258
Applications	1,083	1,102	1,104	984	965	868
Success Rate	29.8%	26.2%	23.4%	26.6%	28.9%	29.7%

- "Success Rate" (grants paid / applications) ≠ "Pay Line"
- FY 2008 competing RPGs average cost \$368K per award.
- FY 2009 competing RPGs average cost increased 3%.

Core Center Grants




Can new Cores be awarded? Yes – but "zero sum budget."

Awarded competitively.

FY 08 Trans-NIH Initiatives





- New Pathways of Discovery *
- Research Teams of the Future
- Re-engineering the Clinical Research Enterprise

Funded through NIH Common Fund				
FY 2007	FY 2008	FY 2009		
\$483.0M	\$498.2M	\$541.1		

New Pathways of Discovery * (Continuing and New Programs)

- Building Blocks, Biological Pathways, and Networks
- Molecular Libraries and Imaging
- Structural Biology
- Bioinformatics and Computational Biology
- Nanomedicine

- Human Microbiome Project
- Epigenomics
- Science of Behavior Change NEW
- New Protein Capture Technologies NEW
- Connectivity Map NEW



Current Funding Opportunities

NIH \$38.6M

Neuroscience Grand Challenges

Specific Challenge Topic: Development of non-invasive imaging approaches of technologies that directly assess neural activity


Other Current Blueprint Funding Opportunites

dissemination, creation of monoclonal antibodies for neurodevelopment research

improved neuroimaging tools and resources

biological assays for automated high throughput screening

Examples: NEI Neuroscience



NEI Clinical Interventions

- Pediatric Eye Disease Investigator Group
 - Focus on strabismus and amblyopia Treatment network, simple protocols, both university- and community-based investigators
 - Plasticity of brain long after traditional wisdom
- Ambylopia in Astigmatic Children
 - Partnership with the Tohono O'odham Nation Epidemiology, treatment trial of spectacles for astigmatism-related amblyopia
- Gene therapy for RPE65 Leber Congenital Amaurosis
- Ciliary Neurotrophic Factor clinical trials in RP patients
- Pre-clinical Gene Therapy for Leber Hereditary Optic Neuropathy

ARRA – American Recovery and Reinvestment Act

www.nei.nih.gov/recovery



- About NEI
- Health Information
- News and Events
- Research Funding
- Research at NEI
- Education Programs
- Jobs
- Training
- Resources

E-mail to a friend



Home » The Role for Vision Research within the American Recovery and Reinvestment Act (ARRA)

The Role for Vision Research within the American Recovery and Reinvestment Act (ARRA)

The American Recovery and Reinvestment Act of 2009
(Recovery Act) was signed into law by President Obama on
February 17th, 2009. It is an unprecedented effort to
jumpstart our economy, create or save millions of jobs, and put
a down payment on addressing long-neglected challenges so
our country can thrive in the 21st century. The Act is an
extraordinary response to a crisis unlike any since the Great
Depression, and includes measures to modernize our nation's
infrastructure, enhance energy independence, expand
educational opportunities, preserve and improve affordable heal

educational opportunities, preserve and improve affordable health care, provide tax relief, and protect those in greatest need." Read the full text (PDF*) of the American Recovery and Reinvestment Act of 2009



Funding Impact

- Stimulate the economy
- Create and preserve jobs
- Expend over 2 years
- Advance biomedical research
- Improve national health

```
$10B - NIH
$174M - NEI
```

Scientific Research Approach

Stimulate and accelerate biomedical research with existing mechanisms

- NEI Research Project Grants (RPGs)
 - R01 Research Project Grant Program
 - R01 Revisions
 - R01 Administrative Supplements
 - R21 Exploratory/Developmental Research Grant Award
 - RC1 Challenge Grants up to \$500K total costs / yr for 2 yr
 - R15 AREA (Academic Research Enhancement Award)
 - Conducted by students and faculty in health professional schools and other academic components
- Signature (U01) (Exceptionally creative projects to address major challenges)
- Cooperative Clinical Research (U10)
- Research & Development Contracts
- Research Management and Support
- Intramural Research Program (Equipment)